Potential probiotics from faecal specimens of breastfed Nigerian infants as a therapy for bacterial gastroenteritis

Adenike A O Ogunshe¹, Abiodun I Sanni², Daniel K Olukoya³

Sri Lanka Journal of Child Health, 2011; 40(3): 116-124

DOI: http://dx.doi.org/10.4038/sljch.v40i3.3509

Abstract

Objective: To investigate the possibility of isolating indigenous probiotic strains from faecal specimens of breastfed infants.

Method: One hundred and sixty four Lactobacillus strains [Lb. reuteri 72 (43.9%), Lb. casei 40 (24.4%), Lb. acidophilus 35 (21.3%), Lb. bifidus 11 (6.71%), Lb. brevis 3 (1.83 %) and Lb. plantarum 3 (1.83 %)] isolated from fresh, faecal specimens of 57 healthy, breastfed Nigerian infants and children <12 months old were assayed for in vitro inhibitory potentials against reference and gastroenteritic bacterial strains, using the modified agar spot and agar well-diffusion methods.

Results: Twenty six (15.9%) of the Lactobacillus strains at 24 hours and 36 months of storage were inhibitory in vitro towards all the gastroenteretic and reference bacteria (Bacillus cereus, Bacillus licheniformis, Citrobacter species, Enterobacter aerogenes, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella enterica var. typhi, Salmonella enterica var. paratyphi, Salmonella enterica var. typhimurium, Salmonella sp., Shigella dysenteriae, Shigella flexneri, Staphylococcus aureus and Yersinia enterocolitica); while only 7 (4.3%) strains were inhibitory at 60 months of storage. The finally selected Lb. reuteri CH1 strain, which was inhibitory against all the indicator and reference bacteria, even at 60 months of storage, also had the lowest antibiotic resistance (23.3%), survived 3% bile and simulated pH conditions of 3.0-9.5.

Conclusions: Potential gastroenteriticidal Lactobacillus probiotic strains with longer shelf-life can be obtained from breastfed faecal specimens of Nigerian infants, more especially children above 5 months old. (Keywords: Breastfeeding; child health; gastroenteritis; infant mortality; Lactobacillus; probiotics)

Background

Gastroenteritis is still a major worldwide problem among infants and children, and one of the principal causes of infantile sickness and death in more than 85% of the world population¹. Although antibiotic therapy has been the mainstay in the treatment of diarrhoeal cases, the onset of drug resistance threatens virtually all classes of antibacterial agents² and though the magnitude of the problem may vary from place to place, the problem of antibiotic resistance is quite alarming in tropical developing countries. Several workers in this country and elsewhere have also highlighted the problems of antibiotic resistance.³ An alternative therapeutic approach, based on oral administration of live bacteria has therefore been under active consideration.⁴⁻⁶⁻⁷⁻⁸

More than 95% of infants in Africa are currently breastfed but feeding practices are often inadequate and the importance of breast milk as a food resource in African countries is also not generally recognised⁹. Although it is important that babies are given extra food, as well as breast milk, at the right age and in sufficient amounts, to enable them grow and stay healthy, new studies on breastfeeding have also discovered or confirmed the benefits of breastfeeding to mother and child¹⁰, while human milk has also been found to contain several antiviral and antibacterial factors¹¹.

In a study with data from India, Peru and Ghana on hospitalisation for diarrhoeal and respiratory illness¹², non-breastfed infants had a higher risk of all causes of hospitalisation when compared to infants who had

¹Lecturer, Applied Microbiology and Infectious Diseases Unit, ²Professor, Food Microbiology Unit, Department of Botany & Microbiology, University of Ibadan, Ibadan, Nigeria, ³Research Scientist, Genetics Unit, Nigeria Institute for Medical Research, P.M.B. 2013, Yaba, Lagos, Nigeria

(Received on 27 June 2010: Accepted after revision on 18 October 2010)
been predominantly breastfed and also had a higher diarrhea-specific hospitalisation. Similarly, non-breastfed infants had higher risk of dying when compared to infants who had been predominantly breastfed. There have been many current attempts to prove the protective factors demonstrated in human milk, and that breastfeeding has a defensive role against various infections in infants. As earlier reported, information about the human flora has mostly been gathered from faeces, and many of the validly described gut Lactobacillus species have been isolated from human faeces\(^1,\)\(^3\) The aim of this study is therefore to determine the possibility of isolating Lactobacillus species from infantile faecal flora of breastfed infants that can serve as probiotics of clinical importance, especially in infantile gastroenteritic therapy.

Methods

**Collection of specimens and isolation of gastroenteritic isolates**

Stool and vomitus specimens were obtained from gastroenteritic epidemic victims in three eastern states of Nigeria and from gastroenteritic patients at Oni Memorial Children Hospital, Ibadan, Nigeria. The stool and vomitus specimens were collected in alkaline peptone water at pH 8.6, and immediately transported to the laboratory for the preliminary microbiological analysis on molten (45\(^0\)C) nutrient agar (NA) (Oxoid, Basingstoke, England), thiosulphate citrate bile sucrose agar (TCBS) (Oxoid) agar, pH 8.2; deoxycholate citrate agar (DCA) (Oxoid), pH 7.2. MacConkey agar (Oxoid), cystein lactose electrolyte deficient agar (CLED) (LAB M, Topley House, Lancashire, England) and Salmonella-Shigella agar (LAB M) at pH 7.4. Representatives of each different bacterial colony types were randomly picked from the primary culture plates of each specimen and sub-cultured on sterile NA and CLED plates by the streaking method. All the pure bacterial isolates from the gastroenteritic specimens were kept in triplicates on Brain Heart Infusion (BHI) (Oxoid) agar slants as working and stock cultures. Final identification analysis was carried out at the Nigeria Institute of Medical Research (NIMR) laboratories according to standard taxonomic tools\(^4,\)\(^5\).

**Isolation and characterisation of Lactobacillus strains**

Ethical approval was granted by the Institute of Child Health and Department of Paediatrics, University College Hospital (UCH), Ibadan, Nigeria for the collection of faecal specimens from subjects at the Institute of Child Health, UCH, Ibadan, Nigeria. Subjects were also solicited by providing questionnaires to parents during their visits to post-natal clinics and at family homes. Questionnaires were completed by providing demographic information and details of feeding patterns of the child prior to collection of the stool specimen. Information sought through the questionnaires included age, sex, term of child at birth (full term, premature or post-mature), feeding patterns of the children and antibiotic therapy within 5 weeks prior to collection of fresh faecal specimens. Faecal specimens of three children who were on antibiotic therapy within the stipulated time period were excluded from analysis.

One ml volumes of overnight MRS broth cultures (de Man, Rogosa and Sharpe, Oxoid, Basingstoke, England) of the infantile faecal specimens from healthy children at pH 5.5-5.7 were separately transferred to sterile Petri dishes by the pour-plate method before incubation anaerobically in 5% CO\(_2\) (Gas Pak Anaerobic System, Oxoid, Basingstoke, England) at 32-35\(^0\)C for 24-48 hours. Representatives of each different bacterial colony type were randomly picked from the primary plates of each specimen and repeatedly sub-cultured on to sterile MRS agar plates to obtain pure cultures.

Different randomly isolated Lactobacillus strains were phenotypically identified at genus and species level by classical tests including the analysis of cell morphology, homo/heterofermentative and biochemical characters, sugar fermentation patterns and growth at different temperatures. The Lactobacillus strains were examined microscopically, and initial confirmation and grouping of the lactobacilli was based on Gram’s reaction, catalase reaction with hydrogen peroxide, growth at 15\(^0\)C and 45\(^0\)C in MRS and medium, gas and acid production from glucose and fermentation of lactose, sucrose, arabinose, fructose and mannitol\(^7\).

The isolates that met the preliminary identification criteria were separately grown in replicates overnight (18–24 hours) in 10ml Rogosa broth at 35\(^0\)C until the weight of the cell mass obtained was 0.05–0.1g. The purity of the strains was checked, and the cells were washed twice in 0.9% sterile NaCl solution after centrifuging. The isolates were then stored at 4\(^0\)C in Hogness freezing buffer (3.6mM K\(_2\)HPO\(_4\); 1.3mM KH\(_2\)PO\(_4\); 2.0mM Na-citrate; 1.0mM MgSO\(_4\); 12% glycerol) and kept frozen. Additional taxonomic studies were carried out on the purified isolates on the basis of their cultural, morphological, biochemical and physiological characteristics and
sugar fermentation patterns. Final identification analysis was carried out at the laboratories of Nigeria Institute of Medical Research (NIMR), Department of Medical Microbiology & Parasitology, University College Hospital, Ibadan and Department of Botany & Microbiology, University of Ibadan according to standard taxonomic tools.\textsuperscript{16,17}

**Antibiotic susceptibility testing**

*Agar disc-diffusion method:* The gastroenteritic bacterial pathogens were assayed for their susceptibility / resistance patterns using the agar disc-diffusion method. Sterile Mueller-Hinton agar, nutrient agar, brain heart infusion agar, tryptone soy agar and MacConkey agar plates were seeded with each of the indicator (gastroenteritic) isolates, after which antibiotic discs commonly used for routine studies in the country, were aseptically placed on the seeded agar surfaces. After overnight incubation at 35°C, zones of inhibition were recorded in mm diameter. Zones less than 10 mm in diameter or absence of zones of inhibition were recorded as negative / no inhibition.

*Modified agar spot-diffusion method:* The antibiotic susceptibility test for the gastroenteritic bacterial species using paediatric antibiotic suspensions was determined according to the modified\textsuperscript{19} agar spot-diffusion method of Tagg and Dajani.\textsuperscript{20} Sterile agar plates were seeded with the indicator organisms by streaking the entire surface of the culture plates (as indicated above), followed by separately dispensing the modified broth cultures (250µl, 500µl, 750µl, 1000µl) (soft agar) of the putative organisms (*Lactobacillus* strains) on the agar surface and incubated at 35°C for 24-48 hours. The demonstration of antagonism depends on the release of a diffusible inhibitor early in the growth phase of the putative microorganisms into the assay media. Inhibitory zones surrounding the putative bacteria were noted and recorded in mm diameter. Zones less than 10 mm in diameter or absence of zones of inhibition were recorded as negative / no inhibition.

*Modified agar well-diffusion method:* The antibiotic susceptibility test for the gastroenteritic bacterial species using paediatric antibiotic suspensions was also determined according to the modified\textsuperscript{19} agar well-diffusion method of Tagg and Dajani.\textsuperscript{20} Holes, 6 mm in diameter were aseptically bored out of sterile agar plates (as indicated above), which were then seeded with the indicator organisms by streaking the entire surface of the agar plates. Modified broth cultures (soft agar) of the putative organisms (250µl, 500µl, 750µl, 1000µl) were separately dispensed into the holes and incubated at 35°C for 24-48 hours. The demonstration of antagonism depends on the release into the assay media of a diffusible inhibitor early in the growth phase of the putative microorganisms. Inhibitory zones surrounding the putative bacteria were noted and recorded in mm diameter. Zones less than 10 mm in diameter or absence of zones of inhibition were recorded as negative / no inhibition.

The oral paediatric antibiotics used with their generics and batch numbers were: Emgyl [metronidazole] (5558F, 6178F), Jawaclox [cloxacillin] (D4078, L4040), Evans metronidazole (3C950007, 3H950006), Barbicillin [ampicillin] (0683, 0800), Suphtim [sulfamethoxazole/trimethoprim] (SS05908, SS04805), Faplox [cloxacillin] (AC065, FG049), Barbimycin [erythromycin] (0080, 0977), Throtal [erythromycin] (TD-017, TD-12), Emtrim [septrin] (3173F, 3051H), Evans cotrimoxazole (5H802013, 4H802012), Bactrim [septrin] (LS24196, Ls24109), Primex [cloxacillin] (03010, 05010), Mopson metronidazole (04-2234, 04-2235), Elgyl [metronidazole] (IU510, IV464) and Nichem ampicillin (A20S, A07S). The antibiotics were all manufactured in Nigeria, as indicated on their packages.

*Detection of antibiotic susceptibility of the Lactobacillus strains:* The most-inhibitory *Lactobacillus* strains from infantile faecal samples were screened for their susceptibility to 17 antibiotics used in clinical practice by the agar disc diffusion method on MRS agar. MRS agar plates seeded with each *Lactobacillus* culture broth were left for about 15 minutes before aseptically placing antibiotic discs on the agar surfaces and incubating the plates anaerobically at 37°C for 18-24 hours. Zones of inhibition and the diameter of the zones were measured and recorded in millimeter diameter. Zones less than 10 mm in diameter or absence of zones of inhibition were recorded as negative / no inhibition.

*Bioassay to determine in vitro inhibitory activities of Lactobacillus species from breast-fed infantile faecal specimens against gastroenteritic bacterial species:* Twenty six *Lactobacillus* strains that exhibited the highest rates of antimicrobial activities against the gastroenteritic indicator (gastroenteritic) organisms within 24 hours and 36 months of storage were further screened for their antimicrobial activities against selected gastroenteritic and reference strains, using the modified agar spot and agar well-diffusion methods. Broth cultures (250, 500 750 and1000µl) of each of the *Lactobacillus* strain were separately dispensed into the agar wells in Mueller-Hinton and
brain-heart infusion agar plates already seeded with the gastroenteric indicator bacterial species. After overnight incubation at 35°C, inhibition observed by a clear zones extending laterally from the border of the producer isolates were noted and recorded in mm diameter. Zones less than 10 mm in diameter or absence of zones of inhibition were recorded as negative / no inhibition.

Results

Gastroenteritic bacterial species isolated from epidemic patients (7 months - 7 years), hospital inpatients (5 months - 5½ years) and hospital outpatients (9 months - 4½ years) assayed for in this study were Bacillus cereus (4), Bacillus licheniformis (5), Citrobacter sp. (1), Enterobacter aerogenes (2), Escherichia coli (5), Klebsiella aerogenes (3), Klebsiella pneumoniae (5), Morganella morganii (1), Proteus mirabilis (3), Proteus vulgaris (1), Pseudomonas aeruginosa (1), Salmonella enterica var. Typhi (1), Salmonella enterica var. Paratyphi (1), Salmonella enterica var. Typhimurium (1), Salmonella sp. (1), Shigella dysenteriae (1), Shigella flexneri (1), Staphylococcus aureus (2) and Yersinia enterocolitica (1).

The viable counts of the infantile faecal specimens were between 1.1 x 10^7 and 7.2 x 10^3 cfu ml^-1. No microbial growth was recorded for faecal specimen CH001, while no lactobacilli was observed in 16 infantile faecal specimens of subjects 4-16 days old. The 164 Lactobacillus strains randomly isolated from faecal specimens of healthy and well-nourished neonates and infants were characterised in this study. Lactobacillus reuteri (43.9%), Lactobacillus casei (24.4%) and Lactobacillus acidophilus (21.3%) were the most prevalent strains, while Lactobacillus bifidus (6.71%), Lactobacillus brevis (1.83%) and Lactobacillus plantarum (1.83%) were also obtained. There was however, a higher recovery rate of Lactobacillus strains from faecal samples of older healthy infants and children (5-11 months).

The Gram-negative bacterial species from epidemic sources (n=10) exhibited very high (70-90%) to total (100%) phenotypic resistance towards amoxicillin, ampicillin, augmentin, cefazone, ceftriazone, chloramphenicol, ciprofloxacin, cotrimoxazole, fortum, gentamicin, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, perfoxacin and tetracycline but lowest resistance (20.0%) were displayed towards claforan. while the resistance rates among the Gram-negative hospital isolates was between 17.6% (tarivid) and 88.2% (amoxicillin, augmentin and ceftiraxone). Antibiotic resistance rates were relatively lower among the Gram-negative gastroenteric bacterial species of hospital sources. Total resistance (100%) rates were also recorded among the Gram-positive bacterial strains (epidemic sources) towards more of the antibiotics - amoxicillin, augmentin, azithromycin, cefuroxime, cephalexin, ciprofloxacin, clindamycin, cloxacillin, colistin, cotrimoxazole, erythromycin, gentamicin, norfloxacin, ofloxacin, penicillin, rocephin, septrin, streptomycin and tetracycline; while similarly higher resistance rates (75.0%) were also exhibited towards claforan and tarivid but lower resistance rates were recorded among the Gram-positive bacteria (Table 1).

The phenotypic antibiotic resistance profiles of the gastroenteritic bacterial isolates from epidemic and hospital specimens showed relatively lower resistance rates towards 30 oral paediatric antibiotic suspensions (when compared to the rates recorded for the antibiotic discs), except towards chloramphenicol, erythromycin, metronidazole and the non-antibiotic anti-gastroenteritic medications (Table 2). However, there were no differences in the antibiotic susceptibility / resistance values on the different culture media.

Twenty six Lactobacillus strains from infantile faecal specimens Lb. reuteri 11 (42.3%) Lb. casei 7 (26.9%), Lb. acidophilus 3 (11.5%), Lb. plantarum 2 (7.7%), Lb. bifidus 1 (3.8%), Lb. brevis 1 (3.8%) exhibited total (100%) in vitro inhibition of the gastroenteritic indicator organisms between 24 hours and 36 months of storage but only 4 (15.3%) Lb. reuteri, 2 (7.7%) Lb. acidophilus and 1 (3.8%) Lb. casei strains were inhibitory towards all the target organisms at 60 months of storage. The finally selected potential probiotic candidate, Lb. reuteri CH1 had the lowest resistance (23.3%) towards the test antibiotics, survived 3% physiological bile, simulated pH (3.0-9.5), and exhibited significant spectrum of inhibitory activities against 7 reference strains and 12 selected gastroenteritic strains from children (Table 3).
### Table 1

**Phenotypic antibiotic resistance profiles of epidemic and hospital Gram-positive and Gram-negative gastroenteritic bacterial isolates**

| Antibiotics     | Gram-positive (% R) |          | Gram-negative (% R) |          |
|------------------|---------------------|----------|---------------------|----------|
|                  | Conc. (µg)          | Epid. (n=4) |          | Conc. (µg)          | Epid. (n=7) |          |
| Amoxicillin      | 25µg                | 100.0    | 100.0              | 25µg                | 100.0    | 88.2    |
| Ampicillin       | 10µg                | 50.0     | 85.7               | 25µg                | 100.0    | 52.9    |
| Augmentin        | 30µg                | 100.0    | 100.0              | 30µg                | 100.0    | 88.2    |
| Azithromycin     | 10µg                | 100.0    | 57.1               | Ceftazone           | 20µg    | 100.0   |
|                  |                     |          |                     | Ceftriazone         | 30µg    | 100.0   |
| Amoxicillin      | 25µg                | 100.0    | 100.0              | 25µg                | 100.0    | 88.2    |
| Ampicillin       | 10µg                | 50.0     | 85.7               | 25µg                | 100.0    | 52.9    |
| Augmentin        | 30µg                | 100.0    | 100.0              | 30µg                | 100.0    | 88.2    |
| Azithromycin     | 10µg                | 100.0    | 57.1               | Ceftazone           | 20µg    | 100.0   |
|                  |                     |          |                     | Ceftriazone         | 30µg    | 100.0   |
| Amoxicillin      | 25µg                | 100.0    | 100.0              | 25µg                | 100.0    | 88.2    |
| Ampicillin       | 10µg                | 50.0     | 85.7               | 25µg                | 100.0    | 52.9    |
| Augmentin        | 30µg                | 100.0    | 100.0              | 30µg                | 100.0    | 88.2    |
| Azithromycin     | 10µg                | 100.0    | 57.1               | Ceftazone           | 20µg    | 100.0   |
|                  |                     |          |                     | Ceftriazone         | 30µg    | 100.0   |
| Amoxicillin      | 25µg                | 100.0    | 100.0              | 25µg                | 100.0    | 88.2    |
| Ampicillin       | 10µg                | 50.0     | 85.7               | 25µg                | 100.0    | 52.9    |
| Augmentin        | 30µg                | 100.0    | 100.0              | 30µg                | 100.0    | 88.2    |
| Azithromycin     | 10µg                | 100.0    | 57.1               | Ceftazone           | 20µg    | 100.0   |
|                  |                     |          |                     | Ceftriazone         | 30µg    | 100.0   |

_Epid. = epidemic patients, Hospt. = hospital patients_

### Table 2

**Phenotypic antibiotic resistance profiles of gastroenteritic bacterial isolates from epidemic and hospital specimens using oral paediatric antibiotic suspensions**

| Antibiotics         | Epidemic bacterial isolates (Vomitus) | Hospital bacterial isolates (Faecal) |
|---------------------|--------------------------------------|-------------------------------------|
|                     | % Phenotypic antibiotic resistance    |                                     |
| Ampicillin-cloxacillin [8] | 46.2                                  | 43.8                                |
| Cephalexin [6]      | 27.2                                  | 27.2                                |
| Chloramphenicol [2] | 100.0                                 | 100.0                               |
| Cotrimoxazole [4]   | 30.6                                  | 43.8                                |
| Erythromycin [2]    | 81.8                                  | 100.0                               |
| Metronidazole [8]   | 77.1                                  | 84.4                                |
| NANT [5]            | 100.0                                 | 100.0                               |

_NANT = non antibiotic anti-gastroenteritic medications_
Table 3

Phenotypic inhibition of indicator bacterial species by the antimicrobial-producing *Lb. reuteri* CH1 at 24, 48 hours incubation at 60 months of storage using modified agar spot and agar well–diffusion methods

| Indicator organisms | Source     | Zones of inhibition (mm diameter) |
|---------------------|------------|-----------------------------------|
|                     |            | 24h                               | 48h | 60m |
| *B. cereus* 25S      | stool      | +(18.0)                           | +(18.0) | +(16.0) |
| *B. licheniformis* 26S | stool      | +(14.0)                           | +(14.0) | +(14.0) |
| *Bacillus* sp.39S    | stool      | +(12.0)                           | +(12.0) | +(12.0) |
| *B. subtilis* NCTC 8236 | Ref. strain | +(18.0)                       | +(18.0) | +(12.0) |
| *Citrobacter* sp.55S | stool      | +(16.0)                           | +(16.0) | +(12.0) |
| *E. coli* K12        | Ref. strain | +(18.0)                       | +(18.0) | +(14.0) |
| *E. coli* V157       | Ref. strain | +(16.0)                       | +(16.0) | +(13.0) |
| *E. coli* NCTC 10418 | Ref. strain | +(18.0)                       | +(18.0) | +(14.0) |
| *E. coli* NCTC 11560 | Ref. strain | +(18.0)                       | +(18.0) | +(14.0) |
| *Kleb. aerogenes* 24S | stool      | +(14.0)                           | +(14.0) | +(12.0) |
| *Kleb. aerogenes* 412S | stool      | +(16.0)                           | +(16.0) | +(15.0) |
| *Kleb. pneumoniae* 29V | vomitus    | +(18.0)                           | +(18.0) | +(13.0) |
| *Kleb. pneumoniae* 32S | stool      | +(16.0)                           | +(16.0) | +(10.0) |
| *Kleb. pneumoniae* 57S | stool      | +(14.0)                           | +(14.0) | +(12.0) |
| *Pr. mirabilis* 22aS | stool      | +(16.0)                           | +(16.0) | +(12.0) |
| *Pr. mirabilis* 22bS | stool      | +(14.0)                           | +(14.0) | +(10.0) |
| *Ps. aeruginosa* 23S | stool      | +(22.0)                           | +(22.0) | +(20.0) |
| *V. cholerae* MA | stool      | +(16.0)                           | +(20.0) | +(16.0) |
| *V. cholerae* INABA | Ref. strain | +(18.0)                       | +(20.0) | +(14.0) |

The values indicate the diameter of inhibition zones in mm with 250µl, 500µl, 750µl and 1000µl of the lactobacilli culture using agar spot and well–diffusion methods at 24hrs, 48hrs and 60 months.

Discussion

In this current study, no culturable colony was obtained from faecal specimen obtained from a 4-day old, low-birth weight, female neonate. As earlier suggested by Blakey et al. and Sakata et al., the absence of bacterial growth may be due to the immaturity of the digestive organs of the subject. Similarly, no lactobacilli were isolated from the faecal specimens of infants below 20 days old, which may be in accordance with the trend in the previous report of Yoshioka et al.25, 27.

Nader de Macias26 had previously documented that *Lb. acidophilus* and *Lb. casei* were the most prevalent *Lactobacillus* species in infantile faecal samples, while Axelson27 also stated that *Lb. acidophilus*, *Lb. fermentum* and *Lb. salivarius* were frequently reported ingredients of the faecal flora, and *Lb. casei*, *Lb. crispatus*, *Lb. gasseri*, *Lb. plantarum*, *Lb. leichmannii* and *Lb. reuteri* were thought to be typical representatives. Isolate identification in the study of Pei-Pei et al.28 also indicated that the infantile faecal *Lactobacillus* species belonged to *Lb. acidophilus*, *Lb. salivarius* and *Lb. paracasei*. The observed inter-species differences in infantile faecal flora between the previous and current findings of this study, in which *Lb. reuteri* and *Lb. acidophilus* were the most prevalent, may be due to differences in diets and geographical locations. Murray29 in carrying out studies on *Enterococcus* spp. similarly reported that *E. faecium* and *E. faecalis* in humans are dependent on geographical location. However, there was no observable difference in the groups of bacterial species isolated from clinical specimens of gastroenteritic epidemic or hospital patients in this study, in comparison to other previous studies. Most of the aetiological agents of gastroenteritis, affecting mainly infants in developing countries are therefore, still of the genera *Bacillus*, *Citrobacter*, *Enterobacter*, *Escherichia coli*, *Klebsiella*, *Morganella*, *Proteus*, *Pseudomonas*, *Salmonella* and *Shigella*, irrespective of the source of the pathogens Pei-Pei, et al.29.

In vitro antimicrobial activities have been known to vary with the infant’s age and according to the different pathogens more common in infants of that age.24 Apart from a strain of *Klebsiella aerogenes* CD332, which was susceptible to all the test antibiotics, the gastroenteritic bacterial isolates were resistant to at least six of the 24 antibiotics tested. Multiple antibiotic resistance (MAR) rates of
Morganella morganii bacterial strains were also observed in this study. It is known that several antimicrobial agents have become available for use in newborns and children with suspected or proven bacterial infections but the in vitro results of the antibiotic susceptibility of the gastroenteritic bacterial isolates to 30 oral paediatric antibiotic suspensions in this study gave relatively higher percentage resistance rates than expected in paediatric chemotherapy, most especially towards cotrimoxazole, metronidazole, erythromycin and chloramphenicol. This shows the great danger these commonly prescribed and abused antibiotics may pose in paediatric infectious conditions in the country, especially with the world-wide problems of antibiotic resistance.

In addition to the clinical and public health implications of antibiotic resistance in paediatric chemotherapy, adverse side effects of such therapy, such as allergic reactions, renal toxicity, gastric intolerance, skin rashes, anaemia, antibiotic-associated diarrhoea etc. are quite numerous and somehow very dangerous to infants and children. However, human breast milk has been reported to contain potential probiotic lactic acid bacteria; therefore, breastfeeding can be a significant source of lactic acid bacteria to the infant gut. The present study highlights the fact that Lactobacillus strains isolated from breastfed infants can clearly inhibit all the test target organisms even at 60 months of storage. Lb. reuteri CH1 isolated from Nigerian breastfed infants had the lowest antibiotic resistance.

The findings of this study indicated the in vitro inhibitory activities of certain Lactobacillus strains towards gastroenteritic and reference bacterial species: Bacillus cereus, Bacillus licheniformis, Citrobacter sp., Enterobacter aerogenes, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella enterica var. Typhi, Salm. enterica var. Paratyphi, Salmonella enterica var. typhimurium, Salmonella sp., Shigella dysenteriae, Shigella flexneri, Staphylococcus aureus and Yersinia enterocolitica, even at 36 and 60 months of storage. The finally selected Lb. reuteri CH1 strain was inhibitory against all the indicator and reference bacteria, even at 60 months of storage, had the lowest antibiotic resistance (23.3%) and survived 3% bile and simulated pH conditions of 3.0-9.5, thereby having the potential properties of a probiotic.

The recovery of potential probiotic Lactobacillus candidates from faecal specimens of healthy breastfed Nigerian infants was confirmed by this study, indicating the beneficial significance of breastfeeding. This data can therefore, be used in promoting breast feeding in children. In addition, the low antibiotic resistance profiles of the probiotic candidates is of utmost importance in that the probiotics are not likely to participate in transferece of antibiotic resistance to other bacterial flora in same ecological niche. Survival of the probiotic candidates in simulated pH conditions also infers their likely ability to survive in the gastrointestinal tracts of children, while producing inhibitory activities against gastroenteritic pathogens.

In conclusion, this study confirms that high quality, antimicrobial-producing Lactobacillus strains can be isolated from faecal specimens of breast-fed infants, especially older babies (5-11 months) who still receive complementary breast-feeding during weaning, thereby suggesting that nursing mothers, especially career-mothers, should not stop breast feeding of their children prematurely.

Acknowledgements

The authors acknowledge especially, Prof. Raffaella Peluzzi, Centro Biologia Alpina Piora, Bellinzona, Switzerland, for provision of bacterial reference strains, Matron Giwa for assistance in obtaining parental consents for the collection of infantile faecal specimens, as well as Prof. (Mrs.) Akinkungbe of the Institute of Child Health and Prof. Nottidge of Department of Paediatric, University College Hospital, Ibadan, for provision of ethical permit.

References

1. Costello A. Hitting the mark: Can under-five mortality be cut by two thirds? Insights Health, 4 September 2003. Available from: http://www.mira.org.np/publication.htm
2. Edgar T, Boyd SD, Palamé MJ. Sustainability for behaviour change in the fight against antibiotic resistance: a social marketing framework J Antimicrob Chemother 2009; 63(2): 230-7.
3. Ogunshe AAO, Kolajo TT. In vitro phenotypic antibiotic resistance in bacterial flora of some indigenous orally consumed herbal medications in Nigeria. J Rural Trop Pub Health 2006; 5: 9-15.
4. Ogunshe AAO, Bakare RA. Evaluation of antimicrobial agents on microbial pathogens of reproductive health importance in a developing country. *J Fam Rep Health* 2009; 3 (1): 9-18.

5. Ogunshe AAO. *In vitro* bactericidal effects and parental acceptance of indigenous probiotics in the control of infantile bacterial gastroenteritis. *Int J Prob Preb* 2006; 1(3/4): 233-44.

6. Vizoso Pinto MG, Franz CMAP, Schillinger U, Holzapfel WH. *Lactobacillus* spp. with *in vitro* probiotic properties from human faeces and traditional fermented products. *Int J Food Microbiol* 2006; 109 (3): 205-14. [http://dx.doi.org/10.1016/j.ijfoodmicro.2006.01.029](http://dx.doi.org/10.1016/j.ijfoodmicro.2006.01.029)

7. Ogunshe AAO, Olaomi JO. *In vitro* phenotypic bactericidal effects of indigenous probiotics on bacterial pathogens implicated in infantile bacterial gastroenteritis using Tukey-HSD test. *Amer J Infect Dis* 2008; 4(2): 162-7. [http://dx.doi.org/10.3844/ajidsp.2008.162.167](http://dx.doi.org/10.3844/ajidsp.2008.162.167)

8. Kale-Pradhan PB, Jassal HK, Wilhelm SM. Role of *Lactobacillus* in the prevention of antibiotic-associated diarrhoea: a meta-analysis. *Pharmacother* 2010; 30(2): 119-26. [http://dx.doi.org/10.1592/phco.30.2.119](http://dx.doi.org/10.1592/phco.30.2.119)

9. Dop MC. Breastfeeding in Africa: will positive trends be challenged by the AIDS epidemic? *Sante* 2002; 12(1): 64-72.

10. WHO/CSTRBPIM. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breast-feeding on the Prevention of Infant Mortality. *Lancet* 2000; 355(9202): 451-5. [http://dx.doi.org/10.1016/S0140-6736(00)82011-5](http://dx.doi.org/10.1016/S0140-6736(00)82011-5)

11. Hansen LA, Karlsson B, Jalil F. Antiviral and antibacterial factors in human milk. In: Hansson LA, editor. Biology of human milk. New York: Raven Press Ltd, 1988. pp. 141-57.

12. Bahl R, Frost C, Kirkwood BR, Edmond K, Martines J, Bhandari N, Arthur P. Infant feeding patterns and risks of death and hospitalization in the first half of infancy: multicentre cohort study. *Bull WHO* 2005; 83(6): 418-26.

13. Klessen B, Bezirtzoglou E, Matto J. Culture-based knowledge on biodiversity, development and stability of human gastrointestinal microflora. *Microb Ecol Health Dis* (supplements), 2000; 2: 53-63.

14. Cheesborough M. District Laboratory Practice in Tropical Countries, Part-2. New York: Cambridge University Press; 2000.

15. De Mann JC, Rogosa M, Sharpe ME. A medium for the cultivation of lactobacilli. *J Appl Bacteriol* 1960; 23: 130-5.

16. Kandler O, Weiss N. The genus: *Lactobacillus*. P. 1208-1260. In Sneath PHA, Mair NS, Sharpe ME, Holt JG, editors. Bergey’s Manual of Systematic Bacteriology, vol.2. Baltimore: Williams and Wilkins, 1986. pp. 1209-34.

17. Molin G, Jeppsson B, Ahnér S, Johansson ML, Nobek S, Stahl M, Bengmark S. Numerical taxonomy of *Lactobacillus* species associated with healthy and diseased mucosa of the human intestines. *J Appl Bacteriol* 1993; 74: 314-23.

18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. NCCLS Document M2A8. 8th edition. USA: Wayne Pa; 2003.

19. Ogunshe AAO. Bioinhibition of diarrheogenic Gram-positive bacterial pathogens by potential indigenous probiotics in industrial infant weaning food. *Asian Pacif J Trop Med* 2008; 1(2), 7711.

20. Tagg JR, Dajani AS. Wannamaker LW. Bacteriocins of Gram-positive bacteria. *Bacteriol Revs* 1976; 40: 722-56.

21. Vallado M, Sandine WE. Standardized method for determining the effect of various antibiotics on lactococcal cultures. *J Food Prot* 1994; 57: 235-9.

22. Elaine E, Vaughan EC, Looney R, O’Rourke N, Coveney H, Daly C, Fitzgerald GF. Isolation from food sources of lactic acid bacteria that produced antimicrobials. *J Appl Bacteriol* 1994; 76: 118-23.
23. Blakey JL, Lubitz L, Barnes GL, Bishop RF, Campbell NT, Gillam GL. Development of gut colonisation in pre-term neonates. *J Med Microbiol* 1982; 15 (4): 519-29. [http://dx.doi.org/10.1099/00222615-15-4-519](http://dx.doi.org/10.1099/00222615-15-4-519)

24. Sakata H, Yoshioka H, Fujita K. Development of the intestinal flora in very low birth weight infants compared to normal full-term newborns. *Eur J Paediatr*, 1985; 144: 186-90.

25. Yoshioka H, Iseki K, Fujita K. Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. *Pediatr* 1983; 72: 317-21.

26. Nader de Macias ME, Apella MC, Romero NC, Gonzalez SN, Oliver G. Inhibition of *Shigella sonnei* by *Lactobacillus casei* and *Lactobacillus acidophilus*. *J Appl Bacteriol* 1992; 73: 407-11.

27. Axelsson L. *Lactobacillus reuteri*, a member of the gut microflora. PhD Dissertation, Swedish University, Sweden. 1990.

28. Pei-Pei L, You-Miin H, Cheng-Chih T. Antagonistic activity of *Lactobacillus acidophilus* RY2 isolated from healthy infancy feces on the growth and adhesion characteristics of enteroaggregative *Escherichia coli*. *Anaer*, 2009; 15 (4): 122-6. [http://dx.doi.org/10.1016/j.anapa.2009.01.009](http://dx.doi.org/10.1016/j.anapa.2009.01.009)

29. Murray BE. The life and times of the *Enterococcus*. *Clinical Microbiol Rev* 1990; 9: 40-62.

30. Siegel JD. Neonatal sepsis. *Semin. Perinatology* 1985; 9: 20.

31. Qin X, Razia Y, Johnson JR, Stapp JR, Boster DR, Tsosie T, Smith DL, Braden CR, Gay K, Angulo FJ, Tarr PI. Ciprofloxacin-resistant Gram-negative bacilli in the fecal microflora of children. *Antimicrob Agents Chemother* 2006; 50 (10): 3325-9. [http://dx.doi.org/10.1128/AAC.00548-06](http://dx.doi.org/10.1128/AAC.00548-06)

32. Ogunshe AAO, Fawole AO, Ajayi VA. Microbial evaluation of public health implications of urine as alternative therapy in paediatric cases. *Pan Afr Med J* 2010; 5 (12):

33. Martín R, Langa S, Reviriego C, Jiminez E, Marin ML, Xaus J, Fernández L, Rodríguez JM. Human milk is a source of lactic acid bacteria for the infant gut. *Pediatr* 2003; 143(6), 754-8.

34. Martín R, Heilig GH, Zoetendal EG, Smidt H, Rodríguez JM. Diversity of the *Lactobacillus* group in breast milk and vagina of healthy women and potential role in the colonization of the infant gut. *J Appl Microbiol* 2007b; 103(6): 2638-44. [http://dx.doi.org/10.1111/j.1365-2672.2007.03497.x](http://dx.doi.org/10.1111/j.1365-2672.2007.03497.x)